CagriSema Weight Loss: REDEFINE Trial Results and Approval Status
CagriSema (cagrilintide plus semaglutide) is still in trials. People lost 20.4% of their body weight on average in its main study so far.
- Average weight lost
- 20.4%
- Trial length
- 68 weeks
- Expected decision
- FDA review in 2026
CagriSema in brief
The 68-week measure showed weight loss as a percent of body weight (REDEFINE 1, vs 3.0% in the placebo group).
Sources: prnewswire.com.
Approved choices and the results from their trials
Outside a trial, a doctor cannot yet prescribe CagriSema (cagrilintide plus semaglutide). Their main weight trials show what these approved medicines can do:
| Trial | Dose group | Average weight lost | Placebo or comparison | Weeks | Who was in it |
|---|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg weekly | 14.9% | 2.4% | 68 | Adults with obesity or overweight, without diabetes |
| OASIS 4 | Wegovy pill 25 mg daily | 13.6% | 2.4% | 64 | Adults with obesity or overweight, without diabetes |
| SURMOUNT-1 | Tirzepatide 15 mg weekly | 20.9% | 3.1% | 72 | Adults with obesity or overweight, without diabetes |
| SURMOUNT-2 | Tirzepatide 15 mg weekly | 14.7% | 3.2% | 72 | Adults who have obesity or overweight along with type 2 diabetes |
| SCALE Obesity and Prediabetes | Liraglutide 3.0 mg daily | 7.4% | 3% | 56 | Obese or overweight adults without type 2 diabetes |
| ATTAIN-1 | Foundayo 17.2 mg daily | 11.1% | 2.1% | 72 | Adults with obesity or overweight, without diabetes |
| ATTAIN-2 | Foundayo 17.2 mg daily | 9.6% | 2.5% | 72 | Adults who have obesity or overweight along with type 2 diabetes |
| STEP 2 | Semaglutide 2.4 mg weekly | 9.6% | 3.4% | 68 | Adults who have obesity or overweight along with type 2 diabetes |
Sources list: STEP 1 (FDA label (DailyMed)), SURMOUNT-1 (FDA label (DailyMed)), SURMOUNT-2 (PubMed), SCALE Obesity and Prediabetes (FDA label (DailyMed)), ATTAIN-1 (FDA label (DailyMed)), STEP 2 (PubMed).